Dr. Hönle AG revised earnings guidance for the year 2021/2022. The Management Board therefore expects sales of EUR 125 million to EUR 130 million and an operating loss (LBIT) of EUR 3 million to EUR 4 million for the Hönle Group in the 2021/2022 financial year. To date, the Executive Board has been expecting sales of between EUR 125 million and EUR 130 million (PY: EUR 115 million) and an operating result (EBIT) of between EUR 9 million and EUR 11 million (PY: EUR 0.3 million).
Market Closed -
Other stock markets
|
Pre-market 02:48:41 am | |||
19.85 EUR | -0.25% | 19.85 | -.--% |
Feb. 26 | Dr. Hönle AG Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
Jan. 25 | Dr. Hönle AG Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+13.43% | 129M | |
+12.62% | 82.83B | |
+17.86% | 69.72B | |
+20.14% | 37.53B | |
+14.52% | 31.66B | |
+12.78% | 27.96B | |
+2.46% | 26.56B | |
+13.70% | 25.65B | |
+2.11% | 25.46B | |
+15.63% | 24.44B |
- Stock Market
- Equities
- HNL Stock
- News Dr. Hönle AG
- Dr. Hönle AG Revises Earnings Guidance for the Year 2021/2022